Chronic rejection is the major cause of long-term heart allograft failure, characterized by tissue infiltration by recipient T cells with indirect allospecificity. Phosphoinositol-3-kinase p110d is a key mediator of T cell receptor signaling, regulating both T cell activation and migration of primed T cells to non-lymphoid antigen-rich tissue. We investigated the effect of genetic or pharmacologic inactivation of PI3K p110d on the development of chronic allograft rejection in a murine model in which HY-mismatched male hearts were transplanted into female recipients. We show that suppression of p110d activity significantly attenuates the development of chronic rejection of heart grafts in the absence of any additional immunosuppressive treatment by impairing the localization of antigen-specific T cells to the grafts, while not inducing specific T cell tolerance. p110d pharmacologic inactivation is effective when initiated after transplantation. Targeting p110d activity might be a viable strategy for the treatment of heart chronic rejection in humans.
Introduction
Chronic rejection is the main cause of late heart allograft failure and the leading cause of death in patients surviving more than 1 year after transplantation [1, 2] . Prominent features of chronic heart graft rejection include proximal coronary artery vasculopathy, occlusion, and eventually loss of cardiac function [1] [2] [3] . These lesions are associated with substantial parenchymal infiltration by T cells [4] . Host immunity -particularly indirect alloresponses mediated by CD4 + T cells, as well as antibodymediated immune responses -to processed fragments of donor major histocompatibility antigens (MHC) and to minor histocompatibility antigens (mHC) have been linked to the development of chronic heart allograft rejection [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
Besides antigen-induced activation, the development of immune responses requires active mechanisms of recruitment of antigenspecific primed T cells into antigenic sites. We and others have shown that T cell receptor (TCR) engagement by antigenpresenting endothelium leads to the migration of antigen-specific memory T cells to non-lymphoid antigen-rich target tissue following priming [16] [17] [18] [19] [20] . This effect is required for the development of a number of T cell-mediated diseases in mice [20] [21] [22] . The effect of TCR ligation on T lymphocyte motility is likely to engage signaling pathways linking TCR triggering to the cytoskeleton. Class IA phosphoinositide 3-kinases (PI3Ks) are a family of p85/p110 heterodimeric lipid kinases that generate second messenger signals (e.g., PIP3) downstream of tyrosine kinases, thereby controlling various cell functions, including motility. PI3K p110d subunit expression is restricted to hematopoietic cells [23] . Following TCR triggering, p110d is recruited by adaptor proteins [24, 25] . Previous studies have shown that mice expressing a catalytically inactive form of p110d (P110d
D910A
) display attenuated T cell-mediated immunity, although p110d D910A mice can be primed against nominal antigens [26] . We have recently shown that, while chemotaxis and constitutive trafficking of memory T lymphocytes with impaired p110d activity are unaffected, these T cells are not susceptible to TCR-mediated T cell recruitment to antigenic sites, which they fail to infiltrate [21] .
In this study, we have investigated the effect of PI3K p110d inactivation on the development of chronic rejection in a murine model of HY-mismatched heart allograft. We show that the establishment of chronic rejection is significantly attenuated in mice lacking p110d activity in the absence of any additional immunosuppressive treatment. The therapeutic effects of p110d inhibition correlated with impaired localization of HY-specific memory T cells to the allografts, but did not induce T cell tolerance. Importantly, PI3K p110d pharmacologic inactivation is effective even when initiated after transplantation. We propose that selective PI3K p110d inhibitors can be developed into an effective therapeutic tool to control chronic heart allograft rejection.
Results
Genetic abrogation of PI3K p110d-signaling prevents Tcell-mediated chronic heart allograft rejection PI3K p110d has been shown to play a critical and nonredundant role in the activation and differentiation of naive T cells [27] . We therefore sought to investigate the effect of inhibition of PI3K p110d signaling on the development of immune-mediated mechanisms of chronic heart allograft rejection. A well-established model involving transplantation of HY-mismatched heart allografts, in which grafts develop pathological features of chronic rejection over time [28] , was adapted for this study. Development of pathology in this model is strictly T cell-dependent, antibodyindependent [29] , and occurs without cessation of the heartbeat [28] . For this reason, histopathologic assessments, rather than survival time points, are provided.
Recipient female WT and p110d D910A mutant mice (bearing an inactive form of p110d [26] ) received either male (antigenic) or female (non-antigenic control) WT hearts. 23 days after transplant, both transplanted and native hearts were harvested and stained with hematoxilin/eosin (HE, representative images in Figure S1 ), and Miller's elastin combined with SMC alpha actin immuno-staining ( Figure 1A ). This time point was selected based on previous monitoring of pathology development (data not shown) and license constraints.
As it is shown in Figure 1 , heart allografts placed into p110d D910A female recipients were protected from the development of vasculopathy as assessed by histopathologic criteria. Costaining of elastine end SMC alpha actin revealed early signs of vasculopathy (narrowing of the lumen and perivascular proliferation of SMC [30] ) in female WT recipient of male hearts, which was inhibited in p110d D910A female recipients ( Figure 1A -B). HE staining of the tissues revealed severe inflammatory lesions in WT female recipients of male hearts, which were significantly attenuated in p110d D910A female recipients ( Figure 1C and Figure S1 ). Female graft and native hearts were free of disease.
Graft infiltration by T cells and macrophages was assessed by immunostaining with FITC-conjugated anti-CD3 and PE-conjugated anti-MAC2 antibodies. As shown in Figure 1D (representative tissue images from each group) and Figure 1E (mean T cell infiltration 6 SD), T cell infiltration of male heart grafted into female p110d D910A mutants was significantly reduced compared with that observed in transplanted male heart grafted into WT female recipients. No difference in T cell infiltration of either female-derived heart grafts or native hearts was observed. Interestingly, no significant difference in the number of infiltrating macrophages was observed in any of the combinations tested. Although p110d has been shown to affect B cell chemotaxis [31] , these data suggest that T cell p110d activity is selectively targeted in this model, in which the development of chronic rejection is strictly T cell-dependent and B cell-independent [28] .
PI3K p110d inhibition does not induce T cell tolerance
PI3K p110d has been reported to contribute to T-cell activation and differentiation [23, 26] . We therefore sought to investigate whether the lack of PI3K p110d activity led to loss of responsiveness by HY-specific T cells following transplantation. Splenocytes from female WT and p110d D910A recipients were harvested 23 days after heart transplantation. T cells were cultured with increasing concentrations of Dby or Uty HY epitope peptides for 48 hours, followed by assessment of thymidine incorporation. As shown in Figure 2 , both WT and p110d
D910A
T cells proliferated in response to HY-derived peptides, suggesting that antigen-specific T cell responsiveness was maintained in mice which did not develop chronic rejection as a result of PI3K p110d inactivation.
PI3K p110d is required for male heart graft infiltration by HY-specific T cells Antigen presentation by graft endothelium has previously been shown to be instrumental to T cell infiltration and rejection of HYmismatched allografts [21, 28] .
Given that PI3K P110d inactivation did not lead to antigenspecific T cell tolerance, we sought to investigate whether the protective effect of abrogation of PI3K p110d signaling selectively prevented antigen-dependent T cell recruitment to HY-mismatched heart graft. C57BL/6 female mice received a syngeneic male (HY-mismatched) or female (non-antigenic) heart transplant. On day 15 post-heart-grafting (i.e. once a memory T cell response is physiologically established [32] ), PKH26-labelled HY-specific H2-A b -restricted CD4
+ WT and CFSE-labeled HY-specific H2-A b -restricted p110d D910A CD4 + T cells (10 7 /mouse) were injected i.v. into female recipients of a WT male heart. The presence of labeled T cells in both transplanted and native hearts was analyzed 24 hours later by wide-field fluorescence microscopy.
As shown in Figure 3 , WT T cells promptly infiltrated male (A) but not female-derived (B) heart grafts, while p110d D910A T cell localization to male transplanted hearts was significantly reduced (A). These results demonstrated that PI3K p110d activity is required for efficient access of HY-specific T cells to male heart grafts. Interestingly, some T cell infiltration was observed in native hearts of both WT and p110d D910A recipients of male hearts, possibly driven by non-specific inflammation induced by the allograft, which was nevertheless unable to induce pathology.
PI3K p110d is not required for constitutive trafficking by memory HY-specific T cells
We have previously suggested that lack of p110d activity specifically affects antigen-driven migration, but not constitutive memory T cell trafficking [21] . The chronic rejection model allowed us to investigate whether this observation holds true in the presence of inflammation. We therefore assessed the migration of HY-specific T cells in sites of constitutive homing in C57BL/6 female recipients of a syngeneic male heart. On day 15 postgrafting, PKH26-labelled HY-specific H2-A b -restricted CD4 + WT and CFSE labeled HY-specific H2-A b -restricted p110d D910A T cells (10 7 /mouse) were injected i.v. into female recipients of a WT male heart. T cell localization in the liver, kidney, lymph node, spleen and gut were assessed 24 hours later by wide-field fluorescence microscopy.
As shown in Figure 4 , both WT and p110d D910A T cells recirculated normally and could be detected in the liver, kidney, lymph node, and spleen of recipient mice in similar numbers. Notably, WT and p110d D910A T cells displayed similar patterns of distribution within the various organs and localized in the liver and kidney in a scattered pattern, while they clustered in restricted areas in lymph nodes. Some T cell infiltration was observed in native hearts, irrespective of p110d activity. These observations further confirm that p110d signaling selectively regulates T cell migration to tissues that do express cognate antigen and it is not required for constitutive trafficking of T cells. Pharmacologic inhibition of PI3K p110d in HYmismatched heart allograft recipients inhibits the development of chronic heart allograft rejection
We have previously shown that PI3K p110d inhibition selectively targets memory T cell trafficking [21] . This opens the possibility that targeting PI3K p110d might be effective in a therapeutic regime. We therefore investigated whether pharmacologic inactivation of PI3K P110d delivered after transplantation at a time when the immune response is already established could prevent the development of chronic rejection. Recipient female WT mice received either syngeneic male or female heart grafts. After 7 days, the selective PI3K p110d inhibitor IC87114 (60mg/ kg/day) or vehicle control was administered i.p. daily for 15 days. Mice were sacrificed 24 hours after the last treatment (day 23). Both transplanted and native hearts were harvested for analysis.
As it is shown in figure 5A , histological analysis showed that treatment with PI3K p110d inhibitor IC87114 prevented the development of pathological signs of chronic rejection (representative images are depicted in Figure S2 panel A). Similarly, T cell infiltration of male heart grafted into WT female mice treated with IC87114 was significantly reduced compared to that observed in transplanted male heart grafted into WT recipient female mice treated with vehicle control ( Figure 5B and Figure S2 panel B). No significant differences in T cell infiltrates were observed in either female-to-female transplanted heart grafts or native hearts. Macrophage infiltrates were often observed, but were of similar magnitude in any donor to recipient combination tested, irrespective of the development of pathology.
Similarly to what we observed in p110d D910A recipients of male hearts, T cells obtained from WT female recipients treated with or D910A mutant mice received male WT transplanted heart. 60 days after transplant, splenocytes from either recipient WT or p110d D910A mutant mice were incubated with different concentrations of Dby and Uty HY peptide epitopes for 48 hours, followed by pulsing with [ WT and CFSE labelled HY-specific H2-A b -restricted p110d D910A T cells were injected i.v. into female mice transplanted with either male (A) or female (B) syngeneic heart. T cell localization in the transplanted heart and native heart were assessed 24 hours later by wide-field fluorescence microscopy. Finally, we sought to establish whether, like genetic inactivation, pharmacological inhibition of P110d selectively affects localization of specific T cells to the heart allograft. Recipient female WT mice received either syngeneic male or female heart grafts. On day 15 post-heart-grafting, PKH26-labelled HY-specific H2-A b -restricted CD4 + WT and CD4 + WT treated with IC87114 (5mM, 1 hour at 37uC) (10 7 /mouse) were injected i.v. into female mice recipients of syngeneic male or female-derived hearts. The presence of labeled T cells in both transplanted and native hearts were analyzed 24 hours later by wide-field fluorescence microscopy. As shown in Figure 5C , untreated T cells promptly localized to male heart grafts, unlike CD4 + WT T cells treated with IC87114. No difference in T cell infiltration was observed in female heart grafts or native hearts. These results suggest that pharmacologic PI3K p110d inactivation is effective at inhibiting access of activated HY-specific T cells to mHC-mismatched heart grafts in a therapeutic regimen.
PI3K p110d inactivation does not prevent rejection of HYmismatched skin
Immune-mediated rejection of vascularized (heart) and nonvascularized (skin) allografts relies upon different mechanisms [21, 28, 33, 34] . Having shown that PI3K p110d inactivation either by genetic mutation or pharmacological inhibition resulted in inhibition of chronic rejection of male heart grafts, we assessed the effect of PI3K p110d inactivation in a model of HY-mismatched skin transplantation. Recipient female WT or p110d D910A mice received WT male skin grafts, and the occurrence of rejection was monitored. Alternatively, WT female recipients of a syngeneic male skin graft were treated daily with PI3K p110d inhibitor IC87114 at 60mg/kg/day or vehicle control 7 days after transplantation until rejection. As it is shown in Figure 6A and 6B, neither genetic nor pharmacological inhibition of PI3K p110d activity led to enhanced skin graft survival. Splenocytes from all groups proliferated equally well to both the HY Dby and Uty epitopes ( Figure S4) .
We further investigated the ability of HY-specific T cells to infiltrate skin grafts. Both male and female skins were grafted onto female recipient mice. On day 20 post-grafting, PKH26-labelled HY-specific H2-A b -restricted CD4 + WT and CFSE labelled HYspecific H2-A b -restricted p110d D910A T cells were injected i.v. into recipient mice. In parallel experiment, HY-specific WT T cells were treated with IC87114 (5mM, 1 hour at 37uC) (10 7 /mouse) or vehicle (DMSO) before injection. The presence of labelled T cells in skin grafts were analyzed 24 hours later by wide-field fluorescence microscopy.
As shown in Figure 7 , inhibition of PI3K p110d activity either by genetic mutation or pharmacological inhibition prevented HYspecific T cell infiltration to male skin grafts. These results suggest that rejection of non-vascularized skin grafts relies upon inflammatory mechanisms other than graft infiltration by antigen-specific T cells.
Discussion
In this study we have investigated the effect of genetic or pharmacologic inactivation of PI3K p110d on the development of chronic allograft rejection in a murine model of mHC (HY)-mismatched heart allograft. We show that inhibition of PI3K p110d activity significantly reduces the development of chronic rejection by inhibiting memory T cell access to the allograft.
Following activation, efficient memory T cell localization to antigen-rich sites requires a sequence of signals, mostly delivered by the endothelium, which include tissue-selective homing interactions such as those mediated by adhesion molecule and chemokine ligand to reach and access target tissue [28, 35] . We and others have shown that efficient recruitment of antigenspecific T cells into antigen-rich sites with promiscuous adhesion/ chemokine receptor/ligand pairs (such as the heart) is optimized by TCR triggering of specific T cells by antigen-presenting endothelium [19, 20, 28, 36] . Importantly, this effect has been shown to support the localization of effector T cells to mHCmismatched heart allograft leading to chronic rejection [28] . We have also reported that antigen-dependent recruitment by the endothelium strictly relies upon PI3K p110d activity, which is initiated upon TCR triggering by MHC:peptide complexes displayed on the endothelial surface [21] .
In our study, the prevention of pathological inflammation leading to chronic rejection by PI3K p110d inhibition correlated with abrogation of antigen-specific T cell access to the transplanted heart. In contrast, loss of PI3K p110d activity did not affect T cell priming in our system, despite evidence suggesting that this mediator is essential and non-redundant for TCR-induced activation of both naïve and memory T cells [27] . While genetic abrogation of PI3K p110d activity might have been compensated for by alternative signaling pathways leading to T cell activation and differentiation, pharmacologic inhibition of PI3K p110d postpriming also appears to selectively affect T cell trafficking to the heart without affecting T cell responsiveness. In the p110d D910A mouse, naive CD4 + T cell proliferation and cytokine production is particularly impaired under suboptimal stimulation conditions (e.g., in the absence of costimulation) [26] . It is possible that PI3K p110d signals contributing to T cell activation might be dispensable when antigen is not limiting, such as in transplantation settings.
The role of macrophages in the development of allograft chronic rejection is still controversial [37] [38] [39] . In our study, . Pharmacologic inhibition of PI3K p110d inhibits chronic heart rejection by preventing T cell access to the graft. Recipient female WT mice received either syngeneic male or female heart grafts. After 7 days, the selective PI3K p110d inhibitor IC87114 (60mg/kg/day) or vehicle control were injected i.p daily for 15 days. Mice were sacrificed 24 hours after the last treatment (day 23). (A) The mean histopathological scores 6 SD of transplanted hearts stained with HE observed in 3 samples obtained from each recipient (at least 3 animals/group) is shown. 0, no inflammation; 1, light focal lymphohistocytic infiltrate; 2, moderate focal lymphohistocytic infiltrate with myocardial involvement; 3, moderate to severe inflammation with focal vasculopathy and myocyte degeneration; 4, severe inflammation, vasculopathy and myocardial fiber loss. **p,0.01 (B) Both transplanted and native hearts were harvested and tissue sections were stained with either FITC-labelled anti-CD3 antibody or PE-labelled anti-MAC2 antibody. The mean T cell infiltration 6 SD observed in samples from at least 3 animals is shown. Filled bar: transplanted heart; Non-filled bar: native heart. *p,0.05. (C) PKH26-labelled HY-specific H2-A b -restricted CD4 + WT and CFSE labelled CD4 + WT treated with IC87114 were injected i.v. into female mice with male syngeneic heart transplantation. T cell localization in the transplanted heart and native heart were assessed 24 hours later by wide-field fluorescence microscopy. Tissue infiltration was quantified by randomly selecting ten 610-magnified fields from tissue samples from at least 3 animals and assessing the number of fluorescent cells in each field. Each panel shows a representative tissue image. The mean T cell infiltration 6 SD observed in samples from at least 3 animals is shown. **p,0.01. doi:10.1371/journal.pone.0032892.g005 p110delta Blockade Inhibits Allograft Rejection PLoS ONE | www.plosone.orgmacrophage infiltration was increased (while not always significantly) in both female (non-antigenic) and male heart transplants compared to native hearts even in the absence of PI3K p110d signaling, suggesting that PI3K p110d activity is not required for monocyte recruitment. However, macrophage infiltration did not affect the clinical outcome, suggesting that either macrophages do not contribute to tissue damage in chronic heart allograft rejection or that a cross talk with infiltrating T cells is necessary for macrophage-mediated pathologic effects.
PI3K p110d inactivation did not affect HY-mismatched skin rejection, despite inhibiting adoptively transferred HY-specific effector T cell access to the skin graft. The immune responses against mHC antigens of skin and heart grafts have been shown to rely upon different immune mechanisms. First, HY-mismatched heart grafts develop chronic T cell infiltrates and vasculopathy over time but the organ remains viable and the heartbeat is maintained. In contrast, HY-mismatched skin grafts fail on average within 3 weeks of transplantation [28] , suggesting that the graft microenvironment (size and antigen presenting cells richness) differently impacts on the strength of the alloresponse. Second, anatomical vascular connection of heart allograft to the host circulation is immediate, while connection of skin graft to the host vascular system occurs within 2-3 weeks post grafting [33, 34, 40] , therefore T cell access to skin grafts is not regulated by endothelial barriers at least in early rejection. Additionally, heart graft endothelium remains of donor origin post grafting [41, 42] , while skin graft re-vascularization partially relies upon cells of host origin [33, 34] . Most importantly, T cell-dependent skin graft rejection can occur acutely in an antigen-independent manner, as H-2b HY-specific, TCR transgenic Mata Hari CD8 + T cells can efficiently reject H-2k skin but not heart allografts [28] . The immune pathway underlying TCR-independent skin rejection has been shown to depend on IFN-c [28] , but its cellular and molecular components have not yet been identified.
Hence, while still inhibiting specific T cell trafficking into the skin, the failure of PI3K p110d inactivation to improve skin graft survival might be due to inflammation-induced mechanisms leading to bystanding damage, related to the temporary lack of regulating endothelial barrier and possibly triggered by overwhelming host cross-reactive T cell responses against skin-harbored microbial antigens. While the heart is contained within a sterile environment inside the body, the skin is continuously exposed to environmental microorganisms.
In summary, the observations described in this study strongly support the concept that pharmacological inactivation of PI3K p110d activity is a viable strategy to control heart allograft chronic rejection. Additional advantages of this approach include the possibility of inhibiting T-cell mediated inflammation in the context of an established immune response (i.e. after transplantation, as we have shown in this study), and the maintenance of immune reactivity, which causes severe side-effect associated with conventional immunosuppressive therapies. In this context, a PI3K p110c?d dual selective inhibitor has been shown to significantly reduce inflammatory injuries in vivo in heart ischemia-reperfusion injury models in rat and pig, while at the same time spare tissue repair processes such as EC mitogenesis [43] . Clearly, the therapeutic application of PI3K p110d inhibition will require careful planning dictated by the organ-specific immunobiology of graft rejection. We propose that this strategy would be very effective in the context of slow-developing T cellinduced inflammation relying upon antigen-dependent trafficking including chronic rejection of vascularized tissue grafts, such as heart transplants, as well as other chronic, T-cell mediated autoimmune diseases such as type I diabetes and multiple sclerosis.
Materials and Methods

Ethics statement
This study was carried out in strict accordance with the Home Office recommendations and under its authority following approval by the Imperial College London/Central Biomedical Services Ethics Committee (REF. PPL 70/5872 and PPL 80/1842). All surgery was performed under anesthesia and all efforts were made to minimize suffering. Animals C57BL/6 mice were purchased from Harlan Olac (Bicester, UK) and used at 7-11 weeks. p110d D910A mice were generated as previously described [26] . Experimental groups included 3-6 animals per group.
Cell culture
Memory CD4
+ T cells specific for the Y-chromosome encoded HY peptide epitope NAGFNSNRANSSRSS and restricted by H2-Ab [44] were obtained from WT and p110d D910A mice by two fortnightly i.p. immunizations of female mice with male C57BL/6 splenocytes, as previously described [45] . The two T cell populations displayed similar specificity, as assessed by [ 3 H]thymidine incorporation, and phenotype, as established by flow cytometry ( Figure S5 ).
Reagents
The HY peptides encoding the Dby and Uty epitopes were kindly provided by Dr. Jian Guo Chai (Imperial College, London, UK). The PI3K p110d inhibitor IC87114 was synthesized as described (D030 from patent WO 01/81346) [27] . IC87114 inhibits p110d kinase activity in cells with an IC 50 between 0.1mM and 0.5mM, and only shows cross-reactivity with other PI3K isoforms at concentrations more than 5mM [27, 46] . In vivo, IC87114 was administered i.p. at a dose of 60 mg/kg. This dose was chosen based on previous reports of its efficacy in vivo [47] . In our hands, a 30 mg/kg by gavage achieves ,2 mM 90 min postadministration and the drug is cleared from the blood 4-7 hours post admin. IC87114 is selective for p110d at plasma concentrations of 5 mM [47] .
The cell linkers PKH26 and CFSE were purchased from SigmaAldrich.
Flow cytometry
For surface staining, cells were labelled with the appropriate concentration of fluorescence-conjugated antibodies or isotype control according to the manufacturer's instructions, and analyzed by a two-laser BD fluorescence activated cell sorter (FACS) Calibur (BD Biosciences, Oxford, UK). Acquired samples were analyzed using Flowjo 7.6 (TreeStar Inc., UK).
T cell proliferation assays
T cells (10 4 /well) isolated from spleen were incubated with irradiated female splenocytes (5610 5 /well) and HY peptides Dby, and Uty (0-100nM) in 96-well flat-bottomed plates. Plate was pulsed 48 hours later with 1mCi/well [ 3 H] thymidine and incubated overnight, then harvested using the Tomtec harvester 96 and filter and counted using the Wallac Microbeta counter for Windows (all from Wallac/Perkin Elmer, Buckinghamshire, UK).
Heart transplantation
Heterotopic heart transplantation was performed in the pathogen-free facilities at Northwick Park Institute for Medical Research (NPIMR, UK) by placing the donor heart into the recipient (WT and p110d D910A ) sternomastoid cavity, connecting the aortal branch to the carotid artery and the pulmonary vein to the jugular vein. Before surgery, mice were given 0.25ml Saline s.c. to prevent dehydration. Anesthetic agents included Ketamine (80-100mg/kg) and Xylazine 10mg/kg. These were administered s.c. mixed in a syringe at a ratio of 2 (Ketamine):1 (Xylazine) diluted with saline 1:1. For analgesia mice were given Rimadyl (Carprofen 50mg/ml), diluted with saline 1:10 s.c.. at a dose of 5mg/kg s.c.. Analgesics were administered prior to surgery and on day one.
To assess the effect of pharmacological inhibition of PI3K p110d activity on graft survival, WT recipients received the selective inhibitor IC87114 at 60mg/kg/day or vehicle control i.p. daily starting 7 days after transplantation and for 15 days.
At the indicated time points, all grafts and native hearts were evaluated by histopathologic criteria in a single-blinded manner (G. Stamp, Histopathology, Imperial College London) and scored to grade the degree of inflammation from 0 to 4 [48] (0, no inflammation; 1, light focal lymphohistocytic infiltrate; 2, moderate focal lymphohistocytic infiltrate with myocardial involvement; 3, moderate to severe inflammation with focal vasculopathy and myocyte degeneration; 4, severe inflammation, vasculopathy and myocardial fiber loss).
Histochemistry
Five-micrometer-thick, paraffin-embedded sections were deparaffinized, rehydrated in graded ethanol. For elastin staining, sections were stained with Miller's elastin followed by immunoperoxidase staining for smooth muscle cells (SMCs) using rabbit monoclonal antibody to mouse SMC alpha actin (clone E184, from Epitomics, California), then counterstained with hematoxylin. For the purpose of comparison, tissue sections were taken in corresponding regions of the heart (proximal ventricular areas). Luminal occlusion was evaluated by tracing the cross-section of each vessel's internal elastic lamina and lumen using Lucia NIS elements software (Nikon UK Ltd., United Kingdom) in three transverse sections per graft. All vessels in each section, which demonstrated clear staining of elastin laminar and presence of SMC alpha-actin, were measured in three sections of each heart [48] . For immunohistochemistry, tissue sections were incubated for 1 h at room temperature with either FITC labelled anti-CD3 antibody or PE labelled anti-MAC2 antibody. Nucleus was counterstained with Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories). Cell infiltration was evaluated by wide field microscopy and automated cell counting.
Skin grafting
Skin grafting was conducted by the method of Billingham and Medawar [16] using tail skin from WT donors grafted onto the lateral thorax of either WT or p110d D910A female mice. Skin graft rejection was assessed as previously described [49] . In the experiments assessing the effect of pharmacological inhibition of p110d activity on graft survival, WT recipients received the selective inhibitor IC87114 at 60mg/kg/day or vehicle control i.p. daily starting 7 days after transplantation and for 15 days. Prior to surgery, mice received medetomidine (1mg/kg), ketamine (75mg/ kg) and atipamezole (2.5mg/kg) s.c..
Recruitment of circulating T cells into tissues
In adoptive transfer experiments HY-specific memory T cells were incubated at 37uC for 10 minutes either with PKH26 (5 mM, red) or CFSE (1 mM, green), washed 3 times with PBS and then co-injected i.v. (10 7 /mouse). After 24 hours, mice were sacrificed and tissues were sampled and embedded in optimal cutting temperature compound (CellPath Ltd, Newtown Powys). Tissue infiltration by T cells was assessed by wide-field fluorescence microscopy 24 hours after injection. The following combinations were used: WT (red) and P110d D910A (green) T cells, WT T cells pre-treated with vehicle (1%DMSO, red) and with PI3K p110d inhibitor IC87114 (5mM for 1 hour at 37uC, green).
Wide-field fluorescence microscopy and automatic cell counting Snap-frozen tissue sections were laid onto Polysine Microscope slides (VWR International), and then mounted in Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories), to stain the nuclei. Slides were visualized with a Coolview 12-cooled CCD camera (Photonic Science) mounted over a Zeiss Axiovert S100 microscope equipped with Metamorph software (Zeiss). Tissue infiltration was quantified by randomly selecting ten 610-magnified fields from tissue samples from at least 3 animals and assessing the number of fluorescent cells in each field. Quantification of T cell infiltrates observed by wide-field fluorescence microscopy was performed using a specifically designed software to run in the LabView (version 7.1; National Instruments) environment. This automatic cell counting algorithm is based on a combination of background subtraction, multiple thresholding, and morphological processing approaches [50] , which allow identification of single fluorescent cells within the tissue. The number of infiltrating labelled cells were then averaged and assessed statistically. Infiltration is expressed as the mean of fluorescent cells per 610 field in a given experimental condition 6 SD.
Statistics
Results are given as the mean per group 6 SD. The data were analyzed using a two-tailed unpaired Student's t test and MannWhitney test. A P value of less than 0.05 was considered significant. Figure S3 Pharmacologic inactivation of PI3K p110d does not induce T cell tolerance. Recipient female WT mice received either syngeneic male or female heart grafts. After 7 days, the selective PI3K p110d inhibitor IC87114 (60mg/kg/day) or vehicle control were injected i.p. daily for 15 days. Mice were sacrificed 24 hours after the last treatment (day 23). Splenocytes obtained from WT female recipients treated with or without IC87114 were incubated with different concentrations of Dby and Uty HY peptide epitopes for 48 hours, followed by pulsing with D910A mutant mice received male skin grafts. After skin grafts were rejected, splenocytes from recipient mice were harvested and incubated with different concentrations of Dby and Uty HY epitopes for 48 hours, followed by pulsing with [ 3 H] thymidine to assess T cell proliferation. (B) Recipient female WT mice received male skin grafts. 7 days after transplant, the PI3K p110d inhibitor IC87114 at 60mg/kg/day or vehicle control were injected i.p. daily until the grafts were rejected. Splenocytes from recipient mice were harvested and incubated with different concentrations of Dby and Uty HY epitopes for 48 hours, followed by pulsing with 
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